NOVOSTEO
Novosteo, Inc. is a startup developing and delivering new drugs for the treatment of bone injury and diseases that impact patients' morbidity, mortality and loss of mobility and productivity associated with bone fractures, bone metastasis and infection. Scientific co-founders Stewart Low and Philip Low of Purdue University have created a proprietary chemistry approach to bone targeting and have discovered novel biologics that accelerate bone regeneration by delivering anabolic agents preferentially to fracture surfaces.
NOVOSTEO
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2017-01-01
Address:
Indiana, Pennsylvania, United States
Country:
United States
Website Url:
http://www.novosteo.com
Total Employee:
1+
Status:
Active
Contact:
765-761-3912
Total Funding:
7.95 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail Amazon Route 53 Amazon S3 CDN Lorem Ipsum
Similar Organizations
1200 Pharma
1200 Pharma is a medicinal chemistry technology company that accelerates pre-clinical drug discovery and clinical approval timelines.
Apic Bio
Apic Bio is a gene therapy company that develops treatment options for rare, undertreated neurological and liver diseases.
Braeburn
Braeburn is dedicated to delivering solutions for people living with the serious consequences of opioid use disorder.
FORMA Therapeutics
FORMA Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative medicines.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
NuChem Sciences
NuChem Sciences is a drug discovery in chemistry contract research organization (CRO) located in Montréal and Lévis.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Kairos Ventures
Kairos Ventures investment in Series A - Novosteo
BioCrossroads
BioCrossroads investment in Series A - Novosteo
Purdue Research Foundation
Purdue Research Foundation investment in Series A - Novosteo
Elevate Ventures
Elevate Ventures investment in Series A - Novosteo
Research Bridge Partners
Research Bridge Partners investment in Seed Round - Novosteo
Purdue Research Foundation
Purdue Research Foundation investment in Pre Seed Round - Novosteo
National Institutes of Health
National Institutes of Health investment in Grant - Novosteo
Official Site Inspections
http://www.novosteo.com
- Host name: s3-website-us-east-1.amazonaws.com
- IP address: 54.231.138.109
- Location: Dublin Ireland
- Latitude: 53.3338
- Longitude: -6.2488
- Timezone: Europe/Dublin
- Postal: D02
More informations about "Novosteo"
Novosteo - Crunchbase Company Profile & Funding
Novosteo, Inc. is a startup developing and delivering new drugs for the treatment of bone injury and diseases that impact patients' morbidity, mortality and loss of mobility and productivity …See details»
Cortexyme acquires Novosteo, rebrands with new …
May 10, 2022 · Despite past troubles tied to its lead drug, Cortexyme is forging ahead with new leadership, the acquisition of skeletal-focused biotech Novosteo and even a name change on the horizon.See details»
Cortexyme Announces Agreement to Acquire Novosteo
The acquisition of Novosteo expands Cortexyme’s drug development pipeline into rare disease indications with the addition of NOV004, a bone targeting molecule designed to accelerate …See details»
Bone treatment startup raises $5.5 M in Series A …
Feb 4, 2021 · Novosteo Inc. is a startup developing and delivering new drugs for the treatment of bone injury and diseases that impact patients’ morbidity, mortality and loss of mobility and productivity associated with bone fractures, bone …See details»
Cortexyme Successfully Completes Acquisition of Novosteo
In conjunction with the close of the Novosteo acquisition, Cortexyme reported that the Compensation Committee of the company’s Board of Directors approved grants of stock …See details»
Cortexyme Successfully Completes Acquisition of …
May 20, 2022 · SOUTH SAN FRANCISCO, Calif.-- ( BUSINESS WIRE )--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients...See details»
Quince Therapeutics acquires Novosteo - 2022-05-10 - Crunchbase
May 10, 2022 · Novosteo Novosteo, test the efficacy of a new drug to help reduce complications from a broken bone due to a fall. Acquiring Organization: Quince Therapeutics Cortexyme is …See details»
Cortexyme Successfully Completes Acquisition of Novosteo
May 20, 2022 · Cortexyme, Inc., a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, …See details»
Cortexyme to Acquire Novosteo, Expanding Pipeline …
May 10, 2022 · The acquisition of Novosteo expands Cortexyme’s drug development pipeline into rare disease indications with the addition of NOV004, a bone targeting molecule designed to accelerate fracture repair, including in …See details»
Injectable pharmaceutical aims to accelerate bone healing, …
Feb 26, 2019 · Orthopaedic Research Society presents first-place award to Novosteo for its work in developing an injectable drug to heal broken bones faster. WEST LAFAYETTE, Ind. – Every …See details»
Novosteo sees growth as it develops injectable drug to …
Sep 23, 2020 · Novosteo Inc. father and son co-founders Philip Low and Stewart Low have been developing and commercializing a targeted drug combination that, when injected, is shown to expedite bone fracture healing. (Purdue Research …See details»
Research Bridge Partners' Portfolio Company, Novosteo, Inc., …
Mar 16, 2021 · Novosteo, Inc. is a startup developing and delivering new drugs for the treatment of bone injury and diseases that impact patients' morbidity, mortality and loss of mobility and …See details»
Bone treatment startup raises $5.5 M in Series A financing
Feb 4, 2021 · Novosteo Inc. is a startup developing and delivering new drugs for the treatment of bone injury and diseases that impact patients’ morbidity, mortality and loss of mobility and …See details»
Bone treatment startup raises $5.5 M in Serie - EurekAlert!
Feb 4, 2021 · Novosteo Inc., a preclinical-stage biotechnology startup focused on the development of bone-targeted therapeutics, announced Thursday (February 4) the closing of a …See details»
Injectable drug aims to accelerate bone healing - Medical Xpress
Feb 26, 2019 · Novosteo, a Purdue-affiliated startup, is advancing a technology shown to repair bone fractures faster and at greater benefit to a patient.See details»
Research Bridge Partners Makes Seed Capital Investment In …
AUSTIN, Texas, Aug. 8, 2019 — Research Bridge Partners—a 501 (c) (3) organization that makes formative investments in biomedical startup companies based on the breakthroughs of …See details»
Injectable drug for faster healing of bone fractures prepares for ...
Feb 11, 2020 · Novosteo, a Purdue-affiliated startup, is advancing a technology shown to repair bone fractures faster and at greater benefit to a patient. The image above shows fractured …See details»
Cortexyme Announces Agreement to Acquire Novosteo
May 10, 2022 · The acquisition of Novosteo expands Cortexyme’s drug development pipeline into rare disease indications with the addition of NOV004, a bone targeting molecule designed to …See details»
Research Bridge Partners’ Portfolio Company, Novosteo, Inc., …
Mar 16, 2021 · Novosteo, Inc. is a startup developing and delivering new drugs for the treatment of bone injury and diseases that impact patients’ morbidity, mortality and loss of mobility and …See details»
Injectable drug for faster healing of bone fr | EurekAlert!
Feb 11, 2020 · image: Novosteo, a Purdue University-affiliated startup, is advancing a technology shown to repair bone fractures faster and at greater benefit to a patient. The image above …See details»